nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Mycophenolate mofetil—psoriasis	0.163	0.224	CbGbCtD
Valsartan—ALB—Acitretin—psoriasis	0.111	0.153	CbGbCtD
Valsartan—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0951	0.131	CbGbCtD
Valsartan—SLCO1B1—Cyclosporine—psoriasis	0.0721	0.0991	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—psoriasis	0.0655	0.09	CbGbCtD
Valsartan—ALB—Mycophenolate mofetil—psoriasis	0.0521	0.0716	CbGbCtD
Valsartan—ALB—Prednisone—psoriasis	0.0416	0.0572	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—psoriasis	0.0381	0.0524	CbGbCtD
Valsartan—CYP2C9—Cholecalciferol—psoriasis	0.0324	0.0445	CbGbCtD
Valsartan—CYP2C9—Cyclosporine—psoriasis	0.0213	0.0292	CbGbCtD
Valsartan—ALB—Methotrexate—psoriasis	0.0209	0.0287	CbGbCtD
Valsartan—CYP2C9—Dexamethasone—psoriasis	0.014	0.0193	CbGbCtD
Valsartan—Irbesartan—JUN—psoriasis	0.00456	0.812	CrCbGaD
Valsartan—AGTR1—Allograft Rejection—IL22—psoriasis	0.00234	0.114	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—REN—psoriasis	0.002	0.0975	CbGpPWpGaD
Valsartan—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00129	0.0629	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE—psoriasis	0.00125	0.0608	CbGpPWpGaD
Valsartan—Losartan—ACE—psoriasis	0.00105	0.188	CrCbGaD
Valsartan—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000798	0.039	CbGpPWpGaD
Valsartan—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000567	0.0277	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-C—psoriasis	0.000443	0.0216	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL13—psoriasis	0.00044	0.0215	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL17A—psoriasis	0.000405	0.0198	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL12B—psoriasis	0.000376	0.0184	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-E—psoriasis	0.000367	0.0179	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000357	0.0174	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000332	0.0162	CbGpPWpGaD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000327	0.016	CbGpPWpGaD
Valsartan—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000287	0.014	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000276	0.0135	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL10—psoriasis	0.000275	0.0134	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—HCAR2—psoriasis	0.000272	0.0133	CbGpPWpGaD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000269	0.0131	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL4—psoriasis	0.000268	0.0131	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-B—psoriasis	0.000262	0.0128	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-A—psoriasis	0.000243	0.0118	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—HLA-DRB1—psoriasis	0.000222	0.0108	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.000194	0.00948	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000185	0.00904	CbGpPWpGaD
Valsartan—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000176	0.000713	CcSEcCtD
Valsartan—Constipation—Cyclosporine—psoriasis	0.000175	0.00071	CcSEcCtD
Valsartan—Dry mouth—Triamcinolone—psoriasis	0.000175	0.000709	CcSEcCtD
Valsartan—Renal failure—Methotrexate—psoriasis	0.000174	0.000707	CcSEcCtD
Valsartan—Angioedema—Betamethasone—psoriasis	0.000174	0.000706	CcSEcCtD
Valsartan—Angioedema—Dexamethasone—psoriasis	0.000174	0.000706	CcSEcCtD
Valsartan—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000173	0.000704	CcSEcCtD
Valsartan—Anorexia—Hydrocortisone—psoriasis	0.000173	0.000703	CcSEcCtD
Valsartan—Diarrhoea—Mycophenolic acid—psoriasis	0.000173	0.000702	CcSEcCtD
Valsartan—Angiopathy—Prednisone—psoriasis	0.000173	0.000701	CcSEcCtD
Valsartan—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000172	0.000699	CcSEcCtD
Valsartan—Immune system disorder—Prednisone—psoriasis	0.000172	0.000698	CcSEcCtD
Valsartan—Oedema—Triamcinolone—psoriasis	0.000171	0.000695	CcSEcCtD
Valsartan—Anaphylactic shock—Triamcinolone—psoriasis	0.000171	0.000695	CcSEcCtD
Valsartan—Vertigo—Betamethasone—psoriasis	0.000171	0.000694	CcSEcCtD
Valsartan—Vertigo—Dexamethasone—psoriasis	0.000171	0.000694	CcSEcCtD
Valsartan—Syncope—Betamethasone—psoriasis	0.000171	0.000693	CcSEcCtD
Valsartan—Syncope—Dexamethasone—psoriasis	0.000171	0.000693	CcSEcCtD
Valsartan—Constipation—Mycophenolate mofetil—psoriasis	0.000171	0.000693	CcSEcCtD
Valsartan—Infection—Triamcinolone—psoriasis	0.00017	0.00069	CcSEcCtD
Valsartan—Hypotension—Hydrocortisone—psoriasis	0.00017	0.000689	CcSEcCtD
Valsartan—Shock—Triamcinolone—psoriasis	0.000168	0.000684	CcSEcCtD
Valsartan—Insomnia—Prednisolone—psoriasis	0.000168	0.000683	CcSEcCtD
Valsartan—Alopecia—Prednisone—psoriasis	0.000168	0.000683	CcSEcCtD
Valsartan—Gastrointestinal pain—Cyclosporine—psoriasis	0.000167	0.000679	CcSEcCtD
Valsartan—Loss of consciousness—Dexamethasone—psoriasis	0.000167	0.000679	CcSEcCtD
Valsartan—Loss of consciousness—Betamethasone—psoriasis	0.000167	0.000679	CcSEcCtD
Valsartan—Dizziness—Mycophenolic acid—psoriasis	0.000167	0.000679	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	0.000167	0.00816	CbGpPWpGaD
Valsartan—Epistaxis—Methotrexate—psoriasis	0.000167	0.000678	CcSEcCtD
Valsartan—Paraesthesia—Prednisolone—psoriasis	0.000167	0.000678	CcSEcCtD
Valsartan—Mental disorder—Prednisone—psoriasis	0.000167	0.000677	CcSEcCtD
Valsartan—Malnutrition—Prednisone—psoriasis	0.000166	0.000673	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000166	0.000672	CcSEcCtD
Valsartan—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000165	0.00803	CbGpPWpGaD
Valsartan—Insomnia—Hydrocortisone—psoriasis	0.000164	0.000667	CcSEcCtD
Valsartan—Paraesthesia—Hydrocortisone—psoriasis	0.000163	0.000663	CcSEcCtD
Valsartan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000163	0.000662	CcSEcCtD
Valsartan—Urticaria—Cyclosporine—psoriasis	0.000162	0.00066	CcSEcCtD
Valsartan—Myalgia—Dexamethasone—psoriasis	0.000162	0.000658	CcSEcCtD
Valsartan—Myalgia—Betamethasone—psoriasis	0.000162	0.000658	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—psoriasis	0.000162	0.0079	CbGpPWpGaD
Valsartan—Abdominal pain—Cyclosporine—psoriasis	0.000162	0.000656	CcSEcCtD
Valsartan—Anxiety—Betamethasone—psoriasis	0.000161	0.000655	CcSEcCtD
Valsartan—Anxiety—Dexamethasone—psoriasis	0.000161	0.000655	CcSEcCtD
Valsartan—Vomiting—Mycophenolic acid—psoriasis	0.000161	0.000652	CcSEcCtD
Valsartan—Dyspepsia—Hydrocortisone—psoriasis	0.00016	0.000649	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—psoriasis	0.00016	0.000649	CcSEcCtD
Valsartan—Rash—Mycophenolic acid—psoriasis	0.000159	0.000647	CcSEcCtD
Valsartan—Dermatitis—Mycophenolic acid—psoriasis	0.000159	0.000646	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—psoriasis	0.000159	0.000646	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—psoriasis	0.000159	0.000646	CcSEcCtD
Valsartan—Urticaria—Mycophenolate mofetil—psoriasis	0.000158	0.000643	CcSEcCtD
Valsartan—Headache—Mycophenolic acid—psoriasis	0.000158	0.000643	CcSEcCtD
Valsartan—Decreased appetite—Hydrocortisone—psoriasis	0.000158	0.000641	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—psoriasis	0.000158	0.000641	CcSEcCtD
Valsartan—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000158	0.00064	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—psoriasis	0.000157	0.000638	CcSEcCtD
Valsartan—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000157	0.000637	CcSEcCtD
Valsartan—Fatigue—Hydrocortisone—psoriasis	0.000157	0.000636	CcSEcCtD
Valsartan—Vision blurred—Prednisone—psoriasis	0.000156	0.000634	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—psoriasis	0.000156	0.000633	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000156	0.000633	CcSEcCtD
Valsartan—Anaphylactic shock—Dexamethasone—psoriasis	0.000155	0.00063	CcSEcCtD
Valsartan—Oedema—Betamethasone—psoriasis	0.000155	0.00063	CcSEcCtD
Valsartan—Oedema—Dexamethasone—psoriasis	0.000155	0.00063	CcSEcCtD
Valsartan—Anaphylactic shock—Betamethasone—psoriasis	0.000155	0.00063	CcSEcCtD
Valsartan—Insomnia—Triamcinolone—psoriasis	0.000155	0.000628	CcSEcCtD
Valsartan—Infection—Betamethasone—psoriasis	0.000154	0.000626	CcSEcCtD
Valsartan—Infection—Dexamethasone—psoriasis	0.000154	0.000626	CcSEcCtD
Valsartan—Paraesthesia—Triamcinolone—psoriasis	0.000154	0.000624	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—HCAR2—psoriasis	0.000153	0.00749	CbGpPWpGaD
Valsartan—Shock—Betamethasone—psoriasis	0.000153	0.00062	CcSEcCtD
Valsartan—Shock—Dexamethasone—psoriasis	0.000153	0.00062	CcSEcCtD
Valsartan—Dyspnoea—Triamcinolone—psoriasis	0.000153	0.000619	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000152	0.00743	CbGpPWpGaD
Valsartan—Nervous system disorder—Betamethasone—psoriasis	0.000152	0.000618	CcSEcCtD
Valsartan—Nervous system disorder—Dexamethasone—psoriasis	0.000152	0.000618	CcSEcCtD
Valsartan—Thrombocytopenia—Betamethasone—psoriasis	0.000152	0.000617	CcSEcCtD
Valsartan—Thrombocytopenia—Dexamethasone—psoriasis	0.000152	0.000617	CcSEcCtD
Valsartan—Angioedema—Prednisone—psoriasis	0.000151	0.000615	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	0.000151	0.00737	CbGpPWpGaD
Valsartan—Hypersensitivity—Cyclosporine—psoriasis	0.000151	0.000612	CcSEcCtD
Valsartan—Dyspepsia—Triamcinolone—psoriasis	0.000151	0.000612	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—CXCL8—psoriasis	0.00015	0.00735	CbGpPWpGaD
Valsartan—Nausea—Mycophenolic acid—psoriasis	0.00015	0.00061	CcSEcCtD
Valsartan—Vertigo—Prednisone—psoriasis	0.000149	0.000604	CcSEcCtD
Valsartan—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000149	0.000603	CcSEcCtD
Valsartan—Syncope—Prednisone—psoriasis	0.000149	0.000603	CcSEcCtD
Valsartan—Anorexia—Betamethasone—psoriasis	0.000148	0.000601	CcSEcCtD
Valsartan—Anorexia—Dexamethasone—psoriasis	0.000148	0.000601	CcSEcCtD
Valsartan—Urticaria—Prednisolone—psoriasis	0.000148	0.0006	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—psoriasis	0.000148	0.000599	CcSEcCtD
Valsartan—Fatigue—Triamcinolone—psoriasis	0.000148	0.000599	CcSEcCtD
Valsartan—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000147	0.000597	CcSEcCtD
Valsartan—Asthenia—Cyclosporine—psoriasis	0.000147	0.000596	CcSEcCtD
Valsartan—Loss of consciousness—Prednisone—psoriasis	0.000146	0.000591	CcSEcCtD
Valsartan—Hypotension—Betamethasone—psoriasis	0.000145	0.000589	CcSEcCtD
Valsartan—Hypotension—Dexamethasone—psoriasis	0.000145	0.000589	CcSEcCtD
Valsartan—Pruritus—Cyclosporine—psoriasis	0.000145	0.000587	CcSEcCtD
Valsartan—Urticaria—Hydrocortisone—psoriasis	0.000144	0.000586	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—psoriasis	0.000144	0.000586	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—psoriasis	0.000144	0.000583	CcSEcCtD
Valsartan—Abdominal pain—Hydrocortisone—psoriasis	0.000144	0.000583	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—psoriasis	0.000143	0.000582	CcSEcCtD
Valsartan—Asthenia—Mycophenolate mofetil—psoriasis	0.000143	0.000581	CcSEcCtD
Valsartan—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000143	0.00697	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000141	0.000574	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000141	0.000574	CcSEcCtD
Valsartan—Pruritus—Mycophenolate mofetil—psoriasis	0.000141	0.000573	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL20—psoriasis	0.000141	0.00689	CbGpPWpGaD
Valsartan—Myalgia—Prednisone—psoriasis	0.000141	0.000573	CcSEcCtD
Valsartan—Arthralgia—Prednisone—psoriasis	0.000141	0.000573	CcSEcCtD
Valsartan—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000141	0.00687	CbGpPWpGaD
Valsartan—Anxiety—Prednisone—psoriasis	0.000141	0.000571	CcSEcCtD
Valsartan—Alopecia—Methotrexate—psoriasis	0.000141	0.000571	CcSEcCtD
Valsartan—Insomnia—Dexamethasone—psoriasis	0.00014	0.00057	CcSEcCtD
Valsartan—Insomnia—Betamethasone—psoriasis	0.00014	0.00057	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.00014	0.000569	CcSEcCtD
Valsartan—Diarrhoea—Cyclosporine—psoriasis	0.00014	0.000568	CcSEcCtD
Valsartan—Paraesthesia—Dexamethasone—psoriasis	0.000139	0.000566	CcSEcCtD
Valsartan—Paraesthesia—Betamethasone—psoriasis	0.000139	0.000566	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—HCAR2—psoriasis	0.000139	0.0068	CbGpPWpGaD
Valsartan—Mental disorder—Methotrexate—psoriasis	0.000139	0.000566	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—psoriasis	0.000138	0.000562	CcSEcCtD
Valsartan—Hypersensitivity—Prednisolone—psoriasis	0.000137	0.000557	CcSEcCtD
Valsartan—Dyspepsia—Dexamethasone—psoriasis	0.000137	0.000555	CcSEcCtD
Valsartan—Dyspepsia—Betamethasone—psoriasis	0.000137	0.000555	CcSEcCtD
Valsartan—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000136	0.000554	CcSEcCtD
Valsartan—Urticaria—Triamcinolone—psoriasis	0.000136	0.000552	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—psoriasis	0.000136	0.00055	CcSEcCtD
Valsartan—Dizziness—Cyclosporine—psoriasis	0.000135	0.000549	CcSEcCtD
Valsartan—Oedema—Prednisone—psoriasis	0.000135	0.000549	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—psoriasis	0.000135	0.000549	CcSEcCtD
Valsartan—Decreased appetite—Betamethasone—psoriasis	0.000135	0.000548	CcSEcCtD
Valsartan—Decreased appetite—Dexamethasone—psoriasis	0.000135	0.000548	CcSEcCtD
Valsartan—Infection—Prednisone—psoriasis	0.000134	0.000545	CcSEcCtD
Valsartan—ALB—Hemostasis—SERPINB8—psoriasis	0.000134	0.00655	CbGpPWpGaD
Valsartan—Gastrointestinal disorder—Betamethasone—psoriasis	0.000134	0.000544	CcSEcCtD
Valsartan—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000134	0.000544	CcSEcCtD
Valsartan—Back pain—Methotrexate—psoriasis	0.000134	0.000544	CcSEcCtD
Valsartan—Hypersensitivity—Hydrocortisone—psoriasis	0.000134	0.000544	CcSEcCtD
Valsartan—Fatigue—Betamethasone—psoriasis	0.000134	0.000543	CcSEcCtD
Valsartan—Fatigue—Dexamethasone—psoriasis	0.000134	0.000543	CcSEcCtD
Valsartan—Shock—Prednisone—psoriasis	0.000133	0.00054	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—psoriasis	0.000133	0.000538	CcSEcCtD
Valsartan—Dizziness—Mycophenolate mofetil—psoriasis	0.000132	0.000536	CcSEcCtD
Valsartan—Skin disorder—Prednisone—psoriasis	0.000131	0.000533	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—psoriasis	0.00013	0.00053	CcSEcCtD
Valsartan—Asthenia—Hydrocortisone—psoriasis	0.00013	0.000529	CcSEcCtD
Valsartan—Vomiting—Cyclosporine—psoriasis	0.00013	0.000528	CcSEcCtD
Valsartan—Rash—Cyclosporine—psoriasis	0.000129	0.000523	CcSEcCtD
Valsartan—Anorexia—Prednisone—psoriasis	0.000129	0.000523	CcSEcCtD
Valsartan—Dermatitis—Cyclosporine—psoriasis	0.000129	0.000523	CcSEcCtD
Valsartan—Pruritus—Hydrocortisone—psoriasis	0.000129	0.000522	CcSEcCtD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	0.000128	0.00626	CbGpPWpGaD
Valsartan—Headache—Cyclosporine—psoriasis	0.000128	0.00052	CcSEcCtD
Valsartan—Gastrointestinal pain—Betamethasone—psoriasis	0.000127	0.000515	CcSEcCtD
Valsartan—Gastrointestinal pain—Dexamethasone—psoriasis	0.000127	0.000515	CcSEcCtD
Valsartan—Vomiting—Mycophenolate mofetil—psoriasis	0.000127	0.000515	CcSEcCtD
Valsartan—Hypersensitivity—Triamcinolone—psoriasis	0.000126	0.000512	CcSEcCtD
Valsartan—Rash—Mycophenolate mofetil—psoriasis	0.000126	0.000511	CcSEcCtD
Valsartan—Dermatitis—Mycophenolate mofetil—psoriasis	0.000126	0.00051	CcSEcCtD
Valsartan—Headache—Mycophenolate mofetil—psoriasis	0.000125	0.000507	CcSEcCtD
Valsartan—Vertigo—Methotrexate—psoriasis	0.000124	0.000505	CcSEcCtD
Valsartan—Diarrhoea—Hydrocortisone—psoriasis	0.000124	0.000505	CcSEcCtD
Valsartan—Urticaria—Betamethasone—psoriasis	0.000123	0.000501	CcSEcCtD
Valsartan—Urticaria—Dexamethasone—psoriasis	0.000123	0.000501	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—psoriasis	0.000123	0.0005	CcSEcCtD
Valsartan—Dizziness—Prednisolone—psoriasis	0.000123	0.0005	CcSEcCtD
Valsartan—Asthenia—Triamcinolone—psoriasis	0.000123	0.000498	CcSEcCtD
Valsartan—Abdominal pain—Betamethasone—psoriasis	0.000123	0.000498	CcSEcCtD
Valsartan—Abdominal pain—Dexamethasone—psoriasis	0.000123	0.000498	CcSEcCtD
Valsartan—Insomnia—Prednisone—psoriasis	0.000122	0.000497	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—VEGFA—psoriasis	0.000122	0.00597	CbGpPWpGaD
Valsartan—Nausea—Cyclosporine—psoriasis	0.000121	0.000493	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—psoriasis	0.000121	0.000493	CcSEcCtD
Valsartan—Pruritus—Triamcinolone—psoriasis	0.000121	0.000492	CcSEcCtD
Valsartan—Cough—Methotrexate—psoriasis	0.000121	0.000491	CcSEcCtD
Valsartan—Dizziness—Hydrocortisone—psoriasis	0.00012	0.000488	CcSEcCtD
Valsartan—Dyspepsia—Prednisone—psoriasis	0.000119	0.000483	CcSEcCtD
Valsartan—Nausea—Mycophenolate mofetil—psoriasis	0.000118	0.000481	CcSEcCtD
Valsartan—Chest pain—Methotrexate—psoriasis	0.000118	0.000479	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—psoriasis	0.000118	0.000479	CcSEcCtD
Valsartan—Myalgia—Methotrexate—psoriasis	0.000118	0.000479	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—psoriasis	0.000118	0.000477	CcSEcCtD
Valsartan—Rash—Prednisolone—psoriasis	0.000117	0.000476	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—psoriasis	0.000117	0.000476	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000117	0.000475	CcSEcCtD
Valsartan—Fatigue—Prednisone—psoriasis	0.000117	0.000473	CcSEcCtD
Valsartan—Headache—Prednisolone—psoriasis	0.000117	0.000473	CcSEcCtD
Valsartan—Constipation—Prednisone—psoriasis	0.000116	0.000469	CcSEcCtD
Valsartan—Vomiting—Hydrocortisone—psoriasis	0.000116	0.000469	CcSEcCtD
Valsartan—Rash—Hydrocortisone—psoriasis	0.000115	0.000465	CcSEcCtD
Valsartan—Dermatitis—Hydrocortisone—psoriasis	0.000114	0.000465	CcSEcCtD
Valsartan—Headache—Hydrocortisone—psoriasis	0.000114	0.000462	CcSEcCtD
Valsartan—Dizziness—Triamcinolone—psoriasis	0.000113	0.000459	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—psoriasis	0.000113	0.000459	CcSEcCtD
Valsartan—ALB—Folate Metabolism—CAT—psoriasis	0.000113	0.0055	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	0.000112	0.00548	CbGpPWpGaD
Valsartan—Infection—Methotrexate—psoriasis	0.000112	0.000456	CcSEcCtD
Valsartan—Asthenia—Betamethasone—psoriasis	0.000111	0.000452	CcSEcCtD
Valsartan—Asthenia—Dexamethasone—psoriasis	0.000111	0.000452	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—psoriasis	0.000111	0.00045	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—psoriasis	0.000111	0.000449	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—psoriasis	0.000111	0.000449	CcSEcCtD
Valsartan—Nausea—Prednisolone—psoriasis	0.000111	0.000449	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CRP—psoriasis	0.00011	0.00537	CbGpPWpGaD
Valsartan—Pruritus—Betamethasone—psoriasis	0.00011	0.000446	CcSEcCtD
Valsartan—Pruritus—Dexamethasone—psoriasis	0.00011	0.000446	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—psoriasis	0.00011	0.000446	CcSEcCtD
Valsartan—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	0.000109	0.00534	CbGpPWpGaD
Valsartan—Vomiting—Triamcinolone—psoriasis	0.000109	0.000442	CcSEcCtD
Valsartan—Nausea—Hydrocortisone—psoriasis	0.000108	0.000438	CcSEcCtD
Valsartan—Rash—Triamcinolone—psoriasis	0.000108	0.000438	CcSEcCtD
Valsartan—Dermatitis—Triamcinolone—psoriasis	0.000108	0.000438	CcSEcCtD
Valsartan—Anorexia—Methotrexate—psoriasis	0.000108	0.000437	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—APOE—psoriasis	0.000108	0.00526	CbGpPWpGaD
Valsartan—Urticaria—Prednisone—psoriasis	0.000107	0.000436	CcSEcCtD
Valsartan—Headache—Triamcinolone—psoriasis	0.000107	0.000435	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—psoriasis	0.000107	0.000434	CcSEcCtD
Valsartan—Diarrhoea—Betamethasone—psoriasis	0.000106	0.000431	CcSEcCtD
Valsartan—Diarrhoea—Dexamethasone—psoriasis	0.000106	0.000431	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000106	0.00518	CbGpPWpGaD
Valsartan—Hypotension—Methotrexate—psoriasis	0.000106	0.000429	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—psoriasis	0.000105	0.00511	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL4—psoriasis	0.000104	0.00506	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000103	0.000418	CcSEcCtD
Valsartan—Dizziness—Betamethasone—psoriasis	0.000103	0.000417	CcSEcCtD
Valsartan—Dizziness—Dexamethasone—psoriasis	0.000103	0.000417	CcSEcCtD
Valsartan—Insomnia—Methotrexate—psoriasis	0.000102	0.000415	CcSEcCtD
Valsartan—Nausea—Triamcinolone—psoriasis	0.000102	0.000413	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—psoriasis	0.000101	0.000412	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	0.000101	0.00494	CbGpPWpGaD
Valsartan—Dyspnoea—Methotrexate—psoriasis	0.000101	0.000409	CcSEcCtD
Valsartan—Somnolence—Methotrexate—psoriasis	0.0001	0.000408	CcSEcCtD
Valsartan—Hypersensitivity—Prednisone—psoriasis	9.96e-05	0.000404	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—psoriasis	9.95e-05	0.000404	CcSEcCtD
Valsartan—Vomiting—Betamethasone—psoriasis	9.87e-05	0.000401	CcSEcCtD
Valsartan—Vomiting—Dexamethasone—psoriasis	9.87e-05	0.000401	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—psoriasis	9.82e-05	0.000399	CcSEcCtD
Valsartan—Rash—Betamethasone—psoriasis	9.79e-05	0.000397	CcSEcCtD
Valsartan—Rash—Dexamethasone—psoriasis	9.79e-05	0.000397	CcSEcCtD
Valsartan—Dermatitis—Dexamethasone—psoriasis	9.78e-05	0.000397	CcSEcCtD
Valsartan—Dermatitis—Betamethasone—psoriasis	9.78e-05	0.000397	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—psoriasis	9.76e-05	0.000396	CcSEcCtD
Valsartan—Fatigue—Methotrexate—psoriasis	9.74e-05	0.000396	CcSEcCtD
Valsartan—Headache—Betamethasone—psoriasis	9.73e-05	0.000395	CcSEcCtD
Valsartan—Headache—Dexamethasone—psoriasis	9.73e-05	0.000395	CcSEcCtD
Valsartan—Asthenia—Prednisone—psoriasis	9.7e-05	0.000394	CcSEcCtD
Valsartan—Pruritus—Prednisone—psoriasis	9.57e-05	0.000388	CcSEcCtD
Valsartan—Diarrhoea—Prednisone—psoriasis	9.25e-05	0.000376	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—psoriasis	9.24e-05	0.000375	CcSEcCtD
Valsartan—Nausea—Dexamethasone—psoriasis	9.22e-05	0.000374	CcSEcCtD
Valsartan—Nausea—Betamethasone—psoriasis	9.22e-05	0.000374	CcSEcCtD
Valsartan—SLCO1B3—Metabolism—NDUFA5—psoriasis	9.14e-05	0.00446	CbGpPWpGaD
Valsartan—Urticaria—Methotrexate—psoriasis	8.98e-05	0.000364	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—CAT—psoriasis	8.96e-05	0.00437	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—CRP—psoriasis	8.95e-05	0.00437	CbGpPWpGaD
Valsartan—Dizziness—Prednisone—psoriasis	8.94e-05	0.000363	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—psoriasis	8.93e-05	0.000363	CcSEcCtD
Valsartan—Vomiting—Prednisone—psoriasis	8.6e-05	0.000349	CcSEcCtD
Valsartan—Rash—Prednisone—psoriasis	8.53e-05	0.000346	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.52e-05	0.00416	CbGpPWpGaD
Valsartan—Dermatitis—Prednisone—psoriasis	8.52e-05	0.000346	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	8.49e-05	0.00415	CbGpPWpGaD
Valsartan—Headache—Prednisone—psoriasis	8.47e-05	0.000344	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—psoriasis	8.33e-05	0.000338	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—HCAR2—psoriasis	8.23e-05	0.00402	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—ICAM1—psoriasis	8.23e-05	0.00402	CbGpPWpGaD
Valsartan—Asthenia—Methotrexate—psoriasis	8.11e-05	0.000329	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	8.1e-05	0.00396	CbGpPWpGaD
Valsartan—Nausea—Prednisone—psoriasis	8.03e-05	0.000326	CcSEcCtD
Valsartan—Pruritus—Methotrexate—psoriasis	7.99e-05	0.000325	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—CCL20—psoriasis	7.97e-05	0.00389	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP2S1—psoriasis	7.77e-05	0.00379	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	7.76e-05	0.00379	CbGpPWpGaD
Valsartan—Diarrhoea—Methotrexate—psoriasis	7.73e-05	0.000314	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	7.69e-05	0.00376	CbGpPWpGaD
Valsartan—Dizziness—Methotrexate—psoriasis	7.47e-05	0.000303	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	7.46e-05	0.00364	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL20—psoriasis	7.24e-05	0.00353	CbGpPWpGaD
Valsartan—Vomiting—Methotrexate—psoriasis	7.18e-05	0.000292	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—TAGAP—psoriasis	7.14e-05	0.00348	CbGpPWpGaD
Valsartan—Rash—Methotrexate—psoriasis	7.12e-05	0.000289	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—psoriasis	7.12e-05	0.000289	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—CRP—psoriasis	7.11e-05	0.00347	CbGpPWpGaD
Valsartan—Headache—Methotrexate—psoriasis	7.08e-05	0.000287	CcSEcCtD
Valsartan—Nausea—Methotrexate—psoriasis	6.71e-05	0.000273	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	6.54e-05	0.00319	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—CP—psoriasis	6.42e-05	0.00313	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	6.4e-05	0.00313	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IFNG—psoriasis	6.26e-05	0.00306	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NDUFA5—psoriasis	6.14e-05	0.003	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.72e-05	0.00279	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	5.71e-05	0.00279	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	5.44e-05	0.00266	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2S1—psoriasis	5.22e-05	0.00255	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—NFKB1—psoriasis	5.21e-05	0.00254	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5e-05	0.00244	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—psoriasis	4.98e-05	0.00243	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—psoriasis	4.97e-05	0.00243	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL20—psoriasis	4.28e-05	0.00209	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	4.14e-05	0.00202	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.07e-05	0.00199	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—psoriasis	4.05e-05	0.00198	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—psoriasis	4.05e-05	0.00198	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—psoriasis	4.02e-05	0.00196	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGAL—psoriasis	3.9e-05	0.0019	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	3.86e-05	0.00189	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—psoriasis	3.81e-05	0.00186	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.79e-05	0.00185	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CARM1—psoriasis	3.79e-05	0.00185	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—psoriasis	3.57e-05	0.00174	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.55e-05	0.00173	CbGpPWpGaD
Valsartan—ALB—Metabolism—NDUFA5—psoriasis	3.51e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.27e-05	0.0016	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—psoriasis	3.27e-05	0.0016	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CP—psoriasis	3.26e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—psoriasis	3.22e-05	0.00157	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	3.11e-05	0.00152	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2S1—psoriasis	2.98e-05	0.00146	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NDUFA5—psoriasis	2.87e-05	0.0014	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.74e-05	0.00134	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.68e-05	0.00131	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.6e-05	0.00127	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CARM1—psoriasis	2.55e-05	0.00124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2S1—psoriasis	2.44e-05	0.00119	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.38e-05	0.00116	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SOCS1—psoriasis	2.35e-05	0.00115	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAT—psoriasis	2.33e-05	0.00114	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TYK2—psoriasis	2.25e-05	0.0011	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	2.15e-05	0.00105	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—psoriasis	1.95e-05	0.000954	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—psoriasis	1.81e-05	0.000885	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.8e-05	0.000878	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—psoriasis	1.74e-05	0.000848	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—psoriasis	1.74e-05	0.000848	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—psoriasis	1.62e-05	0.000791	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—psoriasis	1.6e-05	0.000781	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—psoriasis	1.58e-05	0.000771	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—psoriasis	1.57e-05	0.000766	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.56e-05	0.000763	CbGpPWpGaD
Valsartan—ALB—Metabolism—CARM1—psoriasis	1.46e-05	0.000711	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.36e-05	0.000665	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TYK2—psoriasis	1.33e-05	0.000648	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.28e-05	0.000625	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—psoriasis	1.22e-05	0.000595	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CARM1—psoriasis	1.19e-05	0.000582	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—psoriasis	1.15e-05	0.000564	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.11e-05	0.000544	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—psoriasis	1.1e-05	0.000536	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—psoriasis	1.07e-05	0.000524	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—psoriasis	1.06e-05	0.000518	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKB1—psoriasis	1.03e-05	0.000505	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—psoriasis	9.38e-06	0.000458	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—psoriasis	9.29e-06	0.000453	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—psoriasis	9.27e-06	0.000452	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—psoriasis	8.96e-06	0.000437	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—psoriasis	7.33e-06	0.000358	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—psoriasis	7.09e-06	0.000346	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—psoriasis	7e-06	0.000342	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—psoriasis	6.96e-06	0.00034	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—psoriasis	6.49e-06	0.000317	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—psoriasis	6.06e-06	0.000296	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—psoriasis	5.7e-06	0.000278	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—psoriasis	4.96e-06	0.000242	CbGpPWpGaD
